{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-017461","form_type":"8-K","ticker":"INVA","cik":"0001080014","company_name":"Innoviva, Inc.","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.882171+00:00","generated_at":"2026-05-26T03:11:40.816848+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Innoviva Q4 GSK royalties $66M, IST sales up 47% YoY; ZEVTERA launch mid-2025","bullets":["Q4 GSK royalties $66.0M; full year $255.6M vs $252.7M in 2023.","U.S. net product sales $24.9M in Q4, full year $80.9M (+47% YoY).","Acquired U.S. rights to ZEVTERA; launch expected mid-2025.","Zoliflodacin NDA submission to FDA on track for early 2025.","Cash and receivables $391.4M; net income $20.3M in Q4 ($0.32 EPS)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-017461","json":"https://secwatch.observer/filing/0001104659-25-017461.json","markdown":"https://secwatch.observer/filing/0001104659-25-017461.md","text":"https://secwatch.observer/filing/0001104659-25-017461.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1080014/000110465925017461/0001104659-25-017461-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1080014/000110465925017461/tm257428d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T03:11:40.816848+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}